Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Non SARS-Cov-2 Kits > PCSK9 > EP-103

PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair

For research use only.
  • Background
    PCSK9 is a crucial protein in the regulation of plasma cholesterol homeostasis. It binds low density lipoprotein receptor (LDL R) to enhance the degradation of LDL R. Therefore, inhibition of PCSK9 has been considered a promising strategy to prevent the receptor from being degraded and promote removal of LDL cholesterol from circulation.
  • Application
    This pair is useful for screening for inhibitors of human PCSK9 binding to human LDL R.

    It is for research use only.

  • Reconstitution
    See Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Upon receipt, please store all items at -70°C.

    After reconstitution, the stock solution should be kept at -70°C.

  • Assay Principles
    This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of new PCSK9 pathway inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human LDL R and in-house developed biotinylated PCSK9 protein. This product is uniquely suitable for rapid high-throughput screening of putative PCSK9 inhibitors. Briefly, we provide you with a biotinylated human PCSK9 protein, a human LDL R protein, an anti-PCSK9 neutralizing antibody (as method verified Reference), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    1. Coat the plate with human LDL R.

    2. Add your molecule of interest to the plates.

    3. Add human PCSK9-Biotin to the plates.

    4. Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the ability of your compound to inhibit PCSK9: LDL R binding will be determined by comparing OD readings among different experimental groups.

Typical Data

Serial dilutions of anti-PCSK9 neutralizing antibody (Catalog # PC9-NA003) (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL or 133.33 nM to 0.26 nM) were added into Biotinylated PCSK9: LDL R binding reactions. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Comments (0)

ETD of in-stock products: 2 business days

Price(USD) : $600.00

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:18 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message